Monitor the ISCT presentation on May 6-9 for updated response rates and safety data.
Price Chart
Executive Summary
Tempest Therapeutics will present updated clinical data for TPST-2003 at the ISCT meeting, building on earlier positive interim results showing a 100% complete response rate in six evaluable patients with relapsed/refractory multiple myeloma. The data supports the potential of this dual-targeting CAR-T therapy, but the small sample size and early-stage nature limit near-term impact.
Key Facts
- TPST-2003 is a CD19/BCMA dual-targeting CAR-T therapy for relapsed/refractory multiple myeloma.
- Earlier interim data from the REDEEM-1 trial showed a 100% complete response rate in six evaluable patients.
- Tempest will present updated data at ISCT in Dublin, May 6-9, 2026.
- The trial targets full enrollment of 29 patients and is being conducted by partner Novatim in China.
- Tempest has exclusive rights to develop TPST-2003 outside China, India, Turkey, and Russia.
- Market cap is approximately $24M, making the stock highly sensitive to clinical updates.
Financial Impact
No financial data provided; potential future revenue from TPST-2003 if approved.
Risk Factors
- Very small sample size (6 patients) may not be reproducible in larger trials.
- Early-stage data; further clinical and regulatory hurdles remain.
- High capital needs; dilution risk for this micro-cap stock.
- Historical poor performance of the stock post similar announcements.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3283678 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | DEF 14A | $0.5102 | awaiting T+20 | — | $0.5235 (−2.61%) |
Oct 20, 2026 6d ago | DEFA14A | $0.5282 | awaiting T+20 | — | $0.5235 (−0.89%) |
Oct 20, 2026 6d ago | 8-K | $0.5282 | awaiting T+20 | — | $0.5235 (−0.89%) |
Oct 19, 2026 7d ago | 8-K | $0.5762 | awaiting T+20 | — | $0.5235 (−9.15%) |
Oct 2, 2026 25d ago | EFFECT | $0.8112 | awaiting T+20 | — | $0.5235 (+35.47%) |
Sep 25, 2026 4w ago | S-3 | $0.8316 $0.5102 | ▲ +38.65% | ▲ +38.62% | $0.5235 (+37.05%) |
Sep 17, 2026 5w ago | 8-K | $0.9680 $0.6240 | ▼ −35.54% | ▼ −35.74% | $0.5235 (−45.92%) |
Sep 16, 2026 5w ago | DEFA14A | $0.8950 $0.6350 | ▼ −29.05% | ▼ −30.51% | $0.5235 (−41.51%) |
Sep 16, 2026 5w ago | 8-K | $0.8950 $0.6350 | ▼ −29.05% | ▼ −30.51% | $0.5235 (−41.51%) |
Sep 11, 2026 6w ago | Press Release | $0.8117 $0.7601 | ▲ +6.36% | ▲ +8.23% | $0.5235 (+35.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers